Norfolk

The trials here

What the 7 trials at this site are about, from their registry records.

Conditions

• Asthma1 trial
• Chronic rhinosinusitis with nasal polyps1 trial
• Fatty liver disease (MASLD/MASH)1 trial
• HIV1 trial
• Lupus (SLE)1 trial
• Ovarian cancer1 trial
• Triple-negative breast cancer1 trial

Phase

• Phase 34 trials
• Phase 1/21 trial
• Phase 41 trial

Status

• Completed4 trials
• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• GlaxoSmithKline5 trials
• Tesaro, Inc.1 trial
• ViiV Healthcare1 trial

Running trials

• Recruiting

  A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

  NCT07221227· Phase 3· GlaxoSmithKline· Source

  Contact: John Smith (principal investigator)

• Active, not recruiting

  Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

  NCT04915755· Phase 3· GlaxoSmithKline· Source

• Active, not recruiting

  A Comparison of Platinum-based Therapy With TSR-042 and Niraparib Versus Standard of Care (SOC) Platinum-based Therapy as First-line Treatment of Stage III or IV Nonmucinous Epithelial Ovarian Cancer

  NCT03602859· Phase 3· Tesaro, Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)1 recruiting

Closed trials

• Completed

  A Study Evaluating Implementation Strategies for the Delivery of APRETUDE for Black cis-and Transgender Women in United States EHE Territories

  NCT05514509· Phase 4· ViiV Healthcare· Source

• Completed

  A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

  NCT05496231· Phase 1/2· GlaxoSmithKline· Source

• Completed

  Efficacy and Safety of Depemokimab (GSK3511294) in Participants With Chronic Rhinosinusitis With Nasal Polyps (ANCHOR-2)

  NCT05281523· Phase 3· GlaxoSmithKline· Source

• Completed

  Safety and Effectiveness of BENLYSTA (Belimumab) in Systemic Lupus Erythematosus (SLE) Registry

  NCT01729455· GlaxoSmithKline· Source